Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis 11 Medical and Health Sciences 1117 Public Health and Health Services 11 Medical and Health Sciences 1103 Clinical Sciences

Jordi Gratacós, Caridad Pontes*, Xavier Juanola, Jesús Sanz, Ferran Torres, Cristina Avendaño, Antoni Vallano, Gonzalo Calvo, Eugenio De Miguel, Raimon Sanmartí, Miriam Almirall, Maria Aparicio, Agustí Sellas, Roser Vives, Nestor Albiñana, Mireia Moreno, Teresa Clavaguera, Juan Carlos Torre-Alonso, Raúl Veroz, Carlos Rodríguez-LozanoLuís Francisco Linares, Ana Urruticoechea, Eduardo Collantes, Rosa María Morlà, Dèlia Reina, Eduardo Cuende, Pedro Zarco, Maria Cruz Fernández-Espartero, Rosario García-Vicuña, Carlos Alberto Montilla, Alejandro Villalba, Dora Pascual, Cristina Campos, Antonio Juan, Rafael Ariza, Consuelo Díaz-Miguel, Manuel Maqueda, Maria Pilar Fernández-Dapica, Manuel Fernández-Prada, Enrique Batlle, Carlos González-Fernández, Rubén Queiro

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

13 Citations (Scopus)

Abstract

Objective: The objective was to determine if dose reduction is non-inferior to full-dose TNFi to maintain low disease activity (LDA) in patients already in remission with TNFi, in axial spondyloarthritis. Methods: Randomized, parallel, non-inferiority, open-label multicentre clinical trial. Patients were eligible if they had axial spondyloarthritis and had been in clinical remission for ≥ 6 months with any available TNFi (adalimumab, etanercept, infliximab, golimumab) at the dose recommended by product labelling. Patients were randomized by automated central allocation to continue the same TNFi dose schedule, or to reduce the dose by roughly half according to the protocol. The main outcome was the proportion of subjects with LDA after 1 year. Serious adverse reactions or infections were recorded. Results: The trial stopped due to end of the funding period, after 126 patients were randomized; 113 patients (84.1% male, mean age (SD) 45.6 (13.0) years) were included in the main per-protocol subset. Non-inferiority was concluded for LDA at 1 year (47/55 (83.8%) patients in the full-dose and 48/58 (81.3%) patients in the reduced-dose arm, adjusted difference (95% CI) - 2.5% (- 16.6% to 11.7%)). Serious adverse reactions or infections were reported in 7/62 patients (11.3%) assigned to full dose and 2/61 patients (3.3%) assigned to reduced dose (p value = 0.164). Conclusion: In patients with ankylosing spondylitis in clinical remission for at least 6 months, dose reduction is non-inferior to full TNF inhibitor doses to maintain LDA after 1 year. Serious adverse events may be less frequent with reduced doses. Trial registration: EU Clinical Trials Registry, EudraCT 2011-005871-18 and ClinicalTrials.gov, NCT01604629.

Original languageEnglish
Article number11
Pages (from-to)11
Number of pages10
JournalArthritis Research and Therapy
Volume21
Issue number1
DOIs
Publication statusPublished - 8 Jan 2019

Keywords

  • Dose-tapering
  • Non-inferiority
  • Spondyloarthritis
  • TNF inhibitors

Fingerprint

Dive into the research topics of 'Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis 11 Medical and Health Sciences 1117 Public Health and Health Services 11 Medical and Health Sciences 1103 Clinical Sciences'. Together they form a unique fingerprint.

Cite this